alexa Scholarly Journals In Hematopoietic Stem Cells|OMICS International|Journal Of Cell Science And Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scholarly Journals In Hematopoietic Stem Cells

Scholarly journal is a peer-reviewed journal in which scholarship relating to a particular academic discipline is published. Scholarly journals serve as forums for the introduction and presentation for scrutiny of new research, and the critique of existing research. Content typically takes the form of articles presenting original research, review articles, and book reviews. The term Scholarly journal applies to scholarly publications in all fields; this article discusses the aspects common to all academic field journals. Hematopoietic stem cells (HSCs) are the most routinely transplanted adult stem cell. Currently, they are utilized for the treatment of several genetic and acquired diseases including blood cancers, autoimmune disorders, and hematopoietic defects. Hematopoietic stem cells are ideal candidates for gene therapy applications because they possess the capacity for selfreplication and functionality to propagate the entire hematopoietic lineage, thus facilitating amplification of genetically-modified cells and expression of a transgene product from a multitude of hematopoietic cell types. An additional advantage is the tolerogenic effect Hematopoietic stem cells have on host immunity, which in many contexts, is a barrier to successful gene therapy. Numerous Hematopoietic stem cell-targeted gene therapy studies have been conducted in a range of disease settings. Current pre-clinical research for Hematopoietic stem cell transplantation gene therapy of hemophilia A therapy is focused on i) identification of safe and efficient methods of nucleic acid transfer into Hematopoietic stem cells, ii) optimization of the coagulation factor VIII transgene for high expression, iii) minimization of conditioning regimen-related toxicity with Hematopoietic stem cell engraftment and iv) overcoming complications due to pre-existing factor VIII immunity. Herein, we review the state of the art in Hematopoietic stem cell transplantation gene therapy of hemophilia A. (Zakas PM, Spencer HT, Doering CB, Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on September, 2014